{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 7 of 74', '3', 'Abbreviations', 'AE', 'Adverse event', 'ALP', 'Alkaline phosphatase', 'ALT', 'Alanine aminotransferase', 'ANC', 'Absolute neutrophil count', 'AR', 'Adverse reaction to an investigational medicinal product', 'AST', 'Aspartate aminotransferase', 'CA', 'Competent authority', 'CCF', 'Congestive cardiac failure', 'CCTU-CT', 'Cambridge Clinical Trials Unit - Cancer Theme', 'CI', 'Chief Investigator', 'CR', 'Complete response', 'CRF', 'Case report form', 'CT', 'Computerised tomography', 'CTA', 'Clinical Trial Authorisation', 'CTCAE', 'Common terminology criteria for adverse events', 'ctDNA', 'Circulating tumor deoxyribonucleio acids', 'DMC', 'Data Monitoring Committee', 'DNA', 'Deoxyribonucleic acid', 'DSUR', 'Development Safety Update Report', 'EAS', 'Expanded Access Study', 'ECG', 'Electrocardiogram', 'ECHO', 'Echocardiogram', 'ECOG', 'Eastern Cooperative Oncology Group', 'ECOG PS', 'Eastern Cooperative Oncology Group Performance Status', 'EORTC', 'European Organisation for Research and Treatment of Cancer', 'EU', 'European Union', 'EudraCT', 'European Union Drug Regulating Authorities Clinical Trials', 'FBC', 'Full blood count', 'FDA', 'Food and drug administration', 'GCP', 'Good Clinical Practice', 'GGT', 'Gamma glutamyl transferase', 'GMP', 'Good Manufacturing Practice', 'GP', 'General Practitioner', 'Hb', 'Haemoglobin', 'HR', 'Hazard ratio', 'HRA', 'Health Research Authority', 'ICF', 'Informed consent form', 'IMP', 'Investigational Medicinal Product', 'ISF', 'Investigator Site File', 'IQR', 'Interquartile range', 'ISDMC', 'Independent Safety Data Monitoring Committe', 'ITT', 'Intention-to-treat Population', 'IUD', 'Intrauterine device', 'K', 'Potassium', 'LDH', 'Lactate dehydrogenase', 'LLN', 'Lower Limit of Normal', 'LVEF', 'Left ventricular ejection fraction', 'MAP', 'Mitogen activated protein', 'MHRA', 'Medicines and healthcare products regulatory agency', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 8 of 74', 'MI', 'Myocardial infarction', 'MRI', 'Magnetic resonance imaging', 'Na', 'Sodium', 'NCI', 'National Cancer institute', 'NCI CTCAE', 'National Cancer institute Common terminology Criteria for', 'Adverse Events', 'NHS', 'National Health Service', 'NICE', 'National institute for Health and Care Excellence', 'NIMP', 'Non Investigational Medicinal Product', 'NYHA', 'New York Heart Association', 'os', 'Overall survival', 'PD', 'Progressive disease', 'PFS', 'Progression-free survival', 'PI', 'Principal Investigator', 'PIS', 'Patient Information Sheet', 'PR', 'Partial response', 'PRO', 'Patient reported outcome', 'PRO-CTCAE', 'Patient reported outcomes version of the Common Terminology', 'Criteria for Adverse Events', 'PROMS', 'Patient reported outcome measures', 'PSA', 'Participating site agreement', 'QALY', 'Quality-adjusted life years', 'QoL', 'Quality of life', 'RECIST', 'Response Evaluation Criteria in Solid Tumors', 'R&D', 'Research and Development', 'RA', 'Regulatory Agency', 'REC', 'Research Ethics Committee', 'RfPB', 'Research for Patient Benefit', 'RPED', 'Retinal pigment epithelial detachment', 'RSI', 'Reference safety information', 'RVO', 'Retinal vein occlusion', 'SAE', 'Serious Adverse Event', 'SAR', 'Serious Adverse Reaction', 'SD', 'Stable disease', 'SmPC', 'Summary of Product Characteristics', 'SUSAR', 'Suspected Unexpected Serious Adverse Reaction', 'TIA', 'Transient ischaemic attack', 'TMG', 'Trial Management Group', 'TSC', 'Trial Steering Committee', 'UK', 'United Kingdom', 'ULN', 'Upper limit of normal range', 'WBC', 'White blood cell', 'WCBP', 'Women of child-bearing potential', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}